Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene - 2Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- 3Surveys of Music Collections by Film Stars
- 4NATO official says members often aren't buying weapons together, and it's a mistake
- 5Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- Make your choice for a definitive Christmas getaway destination!
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Turning into a Distributed Writer: My Composing Process
- Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- Australia to offer businesses $693 million in cheap loans to ease fuel cost pressure
